{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:05:07Z","timestamp":1792289107197,"version":"4.4.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["0169-00030B"],"award-info":[{"award-number":["0169-00030B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF23OC0082702"],"award-info":[{"award-number":["NNF23OC0082702"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R389-2021-1596"],"award-info":[{"award-number":["R389-2021-1596"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R389-2021-1596"],"award-info":[{"award-number":["R389-2021-1596"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R389-2021-1596"],"award-info":[{"award-number":["R389-2021-1596"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R389-2021-1596"],"award-info":[{"award-number":["R389-2021-1596"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["K08 MH110610"],"award-info":[{"award-number":["K08 MH110610"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 MH130591"],"award-info":[{"award-number":["R01 MH130591"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P50 DA042012"],"award-info":[{"award-number":["P50 DA042012"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75890-0","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:56:51Z","timestamp":1785790611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networks"],"prefix":"10.1038","volume":"17","author":[{"given":"Frederik","family":"Gudmundsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Czurylo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-0730","authenticated-orcid":false,"given":"Daniel R.","family":"Rijsketic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Trang","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3978-2033","authenticated-orcid":false,"given":"Janika","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naja S.","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0838-0890","authenticated-orcid":false,"given":"Sophie","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5199-9200","authenticated-orcid":false,"given":"Christina","family":"Baun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias M.","family":"Herth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Shalgunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1474-0379","authenticated-orcid":false,"given":"Boris D.","family":"Heifets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-0611","authenticated-orcid":false,"given":"Patrick M.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6014-2084","authenticated-orcid":false,"given":"Mikael","family":"Palner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"75890_CR1","doi-asserted-by":"crossref","unstructured":"Swanson, L. R. Unifying theories of psychedelic drug effects. Front. Pharmacol. 9, 172 (2018).","DOI":"10.3389\/fphar.2018.00172"},{"key":"75890_CR2","doi-asserted-by":"publisher","first-page":"niz003","DOI":"10.1093\/nc\/niz003","volume":"2019","author":"G Scott","year":"2019","unstructured":"Scott, G. & Carhart-Harris, R. L. Psychedelics as a treatment for disorders of consciousness. Neurosci. Conscious. 2019, niz003 (2019).","journal-title":"Neurosci. Conscious."},{"key":"75890_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/643878","volume":"2015","author":"D Gonz\u00e1lez","year":"2015","unstructured":"Gonz\u00e1lez, D., Torrens, M. & Farr\u00e9, M. Acute effects of the novel psychoactive drug 2C-B on emotions. BioMed. Res. Int. 2015, 1\u20139 (2015).","journal-title":"BioMed. Res. Int."},{"key":"75890_CR4","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637\u20131648 (2022).","journal-title":"N. Engl. J. Med."},{"key":"75890_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.31486\/toj.23.0076","volume":"23","author":"L Feulner","year":"2023","unstructured":"Feulner, L., Sermchaiwong, T., Rodland, N. & Galarneau, D. Efficacy and safety of psychedelics in treating anxiety disorders. Ochsner J. 23, 315\u2013328 (2023).","journal-title":"Ochsner J."},{"key":"75890_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser, P. et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.  J. Nerv. Ment. Dis. 202, 513 (2014).","journal-title":"J. Nerv. Ment. Dis."},{"key":"75890_CR7","doi-asserted-by":"publisher","first-page":"1178529","DOI":"10.3389\/fpsyt.2023.1178529","volume":"14","author":"THW Ching","year":"2023","unstructured":"Ching, T. H. W. et al. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive\u2013compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Front Psychiatry 14, 1178529 (2023).","journal-title":"Front Psychiatry"},{"key":"75890_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz, M. P. et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry 79, 953\u2013962 (2022).","journal-title":"JAMA Psychiatry"},{"key":"75890_CR9","doi-asserted-by":"publisher","first-page":"7472","DOI":"10.1523\/JNEUROSCI.1384-23.2023","volume":"43","author":"LP Cameron","year":"2023","unstructured":"Cameron, L. P. et al. Beyond the 5-HT2A receptor: classic and nonclassic targets in psychedelic drug action. J. Neurosci. 43, 7472\u20137482 (2023).","journal-title":"J. Neurosci."},{"key":"75890_CR10","doi-asserted-by":"crossref","unstructured":"Arikci, D. et al. Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants. Neuropsychopharmacol. 51, 1\u20138 (2026)..","DOI":"10.1038\/s41386-026-02428-9"},{"key":"75890_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202200183","volume":"23","author":"C Lenz","year":"2022","unstructured":"Lenz, C. et al. Assessment of bioactivity-modulating pseudo-ring formation in psilocin and related tryptamines. ChemBioChem 23, e202200183 (2022).","journal-title":"ChemBioChem"},{"key":"75890_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s43450-021-00141-w","volume":"31","author":"AC Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves, A. C., Nunes, A. R., Alves, G. & Silva, L. R. Serotonin and melatonin: plant sources, analytical methods, and human health benefits. Rev. Bras. Farmacogn. 31, 162\u2013175 (2021).","journal-title":"Rev. Bras. Farmacogn."},{"key":"75890_CR13","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00204-015-1513-x","volume":"89","author":"AM Ara\u00fajo","year":"2015","unstructured":"Ara\u00fajo, A. M., Carvalho, F., Bastos, M. D. L., Guedes De Pinho, P. & Carvalho, M. The hallucinogenic world of tryptamines: an updated review. Arch. Toxicol. 89, 1151\u20131173 (2015).","journal-title":"Arch. Toxicol."},{"key":"75890_CR14","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.3390\/molecules26092451","volume":"26","author":"P Cumming","year":"2021","unstructured":"Cumming, P. et al. Molecular and functional imaging studies of psychedelic drug action in animals and humans. Molecules 26, 2451 (2021).","journal-title":"Molecules"},{"key":"75890_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44016-1","volume":"14","author":"J Wallach","year":"2023","unstructured":"Wallach, J. et al. Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nat. Commun. 14, 8221 (2023).","journal-title":"Nat. Commun."},{"key":"75890_CR16","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1038\/s41380-023-02280-z","volume":"28","author":"KF Kiilerich","year":"2023","unstructured":"Kiilerich, K. F. et al. Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats. Mol. Psychiatry 28, 3829\u20133841 (2023).","journal-title":"Mol. Psychiatry"},{"key":"75890_CR17","doi-asserted-by":"crossref","unstructured":"Erkizia-Santamar\u00eda I., Alles-Pascual R., Horrillo I., Meana J. J., Ortega J. E. Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. Biomed. Pharmacother. Biomed. Pharmacother. 154, 113612 (2022).","DOI":"10.1016\/j.biopha.2022.113612"},{"key":"75890_CR18","doi-asserted-by":"publisher","first-page":"16940","DOI":"10.1021\/acsomega.0c02208","volume":"5","author":"AR Chadeayne","year":"2020","unstructured":"Chadeayne, A. R., Pham, D. N. K., Reid, B. G., Golen, J. A. & Manke, D. R. Active metabolite of aeruginascin (4-Hydroxy- N, N, N -trimethyltryptamine): synthesis, structure, and serotonergic binding affinity. ACS Omega 5, 16940\u201316943 (2020).","journal-title":"ACS Omega"},{"key":"75890_CR19","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1021\/jm000339w","volume":"43","author":"JB Blair","year":"2000","unstructured":"Blair, J. B. et al. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J. Med. Chem. 43, 4701\u20134710 (2000).","journal-title":"J. Med. Chem."},{"key":"75890_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0028-3908(90)90001-8","volume":"29","author":"DJ Mckenna","year":"1990","unstructured":"Mckenna, D. J., Repke, D. B., Lo, L. & Peroutka, S. J. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology 29, 193\u2013198 (1990).","journal-title":"Neuropharmacology"},{"key":"75890_CR21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/BF02884175","volume":"14","author":"E Kleinerov\u00e1","year":"1969","unstructured":"Kleinerov\u00e1, E. & Kybal, J. Ergot alkaloids. II. On the spectrum of ergot alkaloids contained in the sclerotia of Claviceps purpurea (Fr.) Tul. and Claviceps paspali Stev. et Hall. Folia Microbiol. (Praha) 14, 602\u2013604 (1969).","journal-title":"Folia Microbiol. (Praha)"},{"key":"75890_CR22","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1007\/s00216-016-9322-5","volume":"408","author":"J Nowak","year":"2016","unstructured":"Nowak, J., Wo\u017aniakiewicz, M., Klepacki, P., Sowa, A. & Ko\u015bcielniak, P. Identification and determination of ergot alkaloids in morning glory cultivars. Anal. Bioanal. Chem. 408, 3093\u20133102 (2016).","journal-title":"Anal. Bioanal. Chem."},{"key":"75890_CR23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/252588a0","volume":"252","author":"K Von Hungen","year":"1974","unstructured":"Von Hungen, K., Roberts, S. & Hill, D. F. LSD as an agonist and antagonist at central dopamine receptors. Nature 252, 588\u2013589 (1974).","journal-title":"Nature"},{"key":"75890_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.neuint.2010.01.010","volume":"56","author":"L Minuzzi","year":"2010","unstructured":"Minuzzi, L. & Cumming, P. Agonist binding fraction of dopamine D2\/3 receptors in rat brain: a quantitative autoradiographic study. Neurochem. Int. 56, 747\u2013752 (2010).","journal-title":"Neurochem. Int."},{"key":"75890_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3390\/molecules28020855","volume":"28","author":"CT Nieto","year":"2023","unstructured":"Nieto, C. T., Manchado, A., Belda, L., Diez, D. & Garrido, N. M. 2-Phenethylamines in medicinal chemistry: a review. Molecules 28, 855 (2023).","journal-title":"Molecules"},{"key":"75890_CR26","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1021\/acschemneuro.0c00129","volume":"11","author":"E Marcher-R\u00f8rsted","year":"2020","unstructured":"Marcher-R\u00f8rsted, E. et al. Investigation of the 2,5-dimethoxy motif in phenethylamine serotonin 2A receptor agonists. ACS Chem. Neurosci. 11, 1238\u20131244 (2020).","journal-title":"ACS Chem. Neurosci."},{"key":"75890_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00213-012-2797-7","volume":"225","author":"T P\u00e1len\u00ed\u010dek","year":"2013","unstructured":"P\u00e1len\u00ed\u010dek, T. et al. Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology (Berl.) 225, 75\u201393 (2013).","journal-title":"Psychopharmacology (Berl.)"},{"key":"75890_CR28","doi-asserted-by":"publisher","first-page":"958","DOI":"10.30773\/pi.2021.0209","volume":"18","author":"C-L Yu","year":"2021","unstructured":"Yu, C.-L. et al. Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis. Psychiatry Investig. 18, 958\u2013967 (2021).","journal-title":"Psychiatry Investig."},{"key":"75890_CR29","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.3390\/ijms20246193","volume":"20","author":"M Stampanoni Bassi","year":"2019","unstructured":"Stampanoni Bassi, M., Iezzi, E., Gilio, L., Centonze, D. & Buttari, F. Synaptic plasticity shapes brain connectivity: implications for network topology. Int. J. Mol. Sci. 20, 6193 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"75890_CR30","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"Moliner","year":"2023","unstructured":"Moliner et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat. Neurosci. 26, 1032\u20131041 (2023).","journal-title":"Nat. Neurosci."},{"key":"75890_CR31","doi-asserted-by":"publisher","first-page":"9103","DOI":"10.3390\/ijms21239103","volume":"21","author":"Y-J Lee","year":"2020","unstructured":"Lee, Y.-J. et al. 2-Phenylethylamine (PEA) ameliorates corticosterone-induced depression-like phenotype via the BDNF\/TrkB\/CREB signaling pathway. Int. J. Mol. Sci. 21, 9103 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"75890_CR32","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly, C. et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 23, 3170\u20133182 (2018).","journal-title":"Cell Rep."},{"key":"75890_CR33","doi-asserted-by":"crossref","unstructured":"Shao, L. -X. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109, 2535\u20132544 (2021).","DOI":"10.1016\/j.neuron.2021.06.008"},{"key":"75890_CR34","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0269881120959614","volume":"35","author":"OH Jefsen","year":"2021","unstructured":"Jefsen, O. H., Elfving, B., Wegener, G. & M\u00fcller, H. K. Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. J. Psychopharmacol. 35, 483\u2013493 (2021).","journal-title":"J. Psychopharmacol."},{"key":"75890_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/ijms22020835","volume":"22","author":"NR Raval","year":"2021","unstructured":"Raval, N. R. et al. A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. Int. J. Mol. Sci. 22, 835 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"75890_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1875397300802010062","volume":"2","author":"JT Ting","year":"2008","unstructured":"Ting, J. T. & Feng, G. Glutamatergic synaptic dysfunction and obsessive\u2013compulsive disorder. Curr. Chem. Genomics 2, 62\u201375 (2008).","journal-title":"Curr. Chem. Genomics"},{"key":"75890_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.conb.2014.08.008","volume":"30","author":"E Burgui\u00e8re","year":"2015","unstructured":"Burgui\u00e8re, E., Monteiro, P., Mallet, L., Feng, G. & Graybiel, A. M. Striatal circuits, habits, and implications for obsessive\u2013compulsive disorder. Curr. Opin. Neurobiol. 30, 59\u201365 (2015).","journal-title":"Curr. Opin. Neurobiol."},{"key":"75890_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrn3945","volume":"16","author":"P Tovote","year":"2015","unstructured":"Tovote, P., Fadok, J. P. & L\u00fcthi, A. Neuronal circuits for fear and anxiety. Nat. Rev. Neurosci. 16, 317\u2013331 (2015).","journal-title":"Nat. Rev. Neurosci."},{"key":"75890_CR39","doi-asserted-by":"crossref","unstructured":"Calz\u00e0, J., G\u00fcrsel, D. A., Schmitz-Koep, B. & Koch, K. Altered cortico\u2013striatal functional connectivity during resting state in obsessive\u2013compulsive disorder. Front. Psychiatry 10, 319 (2019).","DOI":"10.3389\/fpsyt.2019.00319"},{"key":"75890_CR40","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s12264-018-0214-x","volume":"34","author":"Y Zhu","year":"2018","unstructured":"Zhu, Y., Jiang, X. & Ji, W. The mechanism of cortico\u2013striato\u2013thalamo\u2013cortical neurocircuitry in response inhibition and emotional responding in attention deficit hyperactivity disorder with comorbid disruptive behavior disorder. Neurosci. Bull. 34, 566\u2013572 (2018).","journal-title":"Neurosci. Bull."},{"key":"75890_CR41","doi-asserted-by":"publisher","first-page":"e3000","DOI":"10.1002\/brb3.3000","volume":"13","author":"B Jalal","year":"2023","unstructured":"Jalal, B., Chamberlain, S. R. & Sahakian, B. J. Obsessive\u2013compulsive disorder: etiology, neuropathology, and cognitive dysfunction. Brain Behav. 13, e3000 (2023).","journal-title":"Brain Behav."},{"key":"75890_CR42","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/ijms22020853","volume":"22","author":"C-J Hsu","year":"2021","unstructured":"Hsu, C.-J., Wong, L.-C. & Lee, W.-T. Immunological dysfunction in tourette syndrome and related disorders. Int. J. Mol. Sci. 22, 853 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"75890_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s11689-023-09501-0","volume":"15","author":"C-J Hsu","year":"2023","unstructured":"Hsu, C.-J. et al. The microstructural change of the brain and its clinical severity association in pediatric Tourette syndrome patients. J. Neurodev. Disord. 15, 34 (2023).","journal-title":"J. Neurodev. Disord."},{"key":"75890_CR44","doi-asserted-by":"crossref","unstructured":"Peters, S. K., Dunlop, K. & Downar, J. Cortico-striatal-thalamic loop circuits of the salience network: a central pathway in psychiatric disease and treatment. Front. Syst. Neurosci. 10, 104 (2016).","DOI":"10.3389\/fnsys.2016.00104"},{"key":"75890_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105039","volume":"146","author":"L Pessoa","year":"2023","unstructured":"Pessoa, L. How many brain regions are needed to elucidate the neural bases of fear and anxiety? Neurosci. Biobehav Rev. 146, 105039 (2023).","journal-title":"Neurosci. Biobehav Rev."},{"key":"75890_CR46","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41583-018-0039-7","volume":"19","author":"RJ Fenster","year":"2018","unstructured":"Fenster, R. J., Lebois, L. A. M., Ressler, K. J. & Suh, J. Brain circuit dysfunction in post-traumatic stress disorder: from mouse to man. Nat. Rev. Neurosci. 19, 535\u2013551 (2018).","journal-title":"Nat. Rev. Neurosci."},{"key":"75890_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.24","volume":"3","author":"MG Craske","year":"2017","unstructured":"Craske, M. G. et al. Anxiety disorders. Nat. Rev. Dis. Prim. 3, 17024 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"75890_CR48","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.biopsych.2008.08.022","volume":"65","author":"K Roelofs","year":"2009","unstructured":"Roelofs, K. et al. Hypothalamus-pituitary-adrenal axis hyperresponsiveness is associated with increased social avoidance behavior in social phobia. Biol. Psychiatry 65, 336\u2013343 (2009).","journal-title":"Biol. Psychiatry"},{"key":"75890_CR49","doi-asserted-by":"publisher","first-page":"9878","DOI":"10.1523\/JNEUROSCI.1138-17.2019","volume":"39","author":"WW Seeley","year":"2019","unstructured":"Seeley, W. W. The salience network: a neural system for perceiving and responding to homeostatic demands. J. Neurosci. 39, 9878\u20139882 (2019).","journal-title":"J. Neurosci."},{"key":"75890_CR50","doi-asserted-by":"crossref","unstructured":"A. S. Klein et al. Fear balance is maintained by bodily feedback to the insular cortex in mice. Science 374, 1010\u20131015.","DOI":"10.1126\/science.abj8817"},{"key":"75890_CR51","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.tins.2013.07.001","volume":"36","author":"P Mergenthaler","year":"2013","unstructured":"Mergenthaler, P., Lindauer, U., Dienel, G. A. & Meisel, A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 36, 587\u2013597 (2013).","journal-title":"Trends Neurosci."},{"key":"75890_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39005-8","volume":"9","author":"M Veronese","year":"2019","unstructured":"Veronese, M. et al. Covariance statistics and network analysis of brain PET imaging studies. Sci. Rep. 9, 2496 (2019).","journal-title":"Sci. Rep."},{"key":"75890_CR53","doi-asserted-by":"crossref","unstructured":"Mm, H. et al. Total synthesis and evaluation of [18F]MHMZ. Bioorgan. Med. Chem. Lett. 18, 1515\u20131519 (2008).","DOI":"10.1016\/j.bmcl.2007.12.054"},{"key":"75890_CR54","doi-asserted-by":"crossref","unstructured":"Taylor, P. A. et al. Go Figure: transparency in neuroscience images preserves context and clarifies interpretation. Preprint at https:\/\/arxiv.org\/abs\/2504.07824 (2025).","DOI":"10.1038\/s41592-026-03206-7"},{"key":"75890_CR55","doi-asserted-by":"publisher","unstructured":"McCulloch, D. E.-W. et al. Molecular, haemodynamic, and functional effects of LSD in the human brain. Preprint at https:\/\/doi.org\/10.1101\/2025.06.17.25329677 (2025).","DOI":"10.1101\/2025.06.17.25329677"},{"key":"75890_CR56","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen, M. K. et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacol 44, 1328\u20131334 (2019).","journal-title":"Neuropsychopharmacol"},{"key":"75890_CR57","doi-asserted-by":"crossref","unstructured":"Maltby, C. J. et al. An exploration of the relationships between the effects of psilocybin on behavior, 5-HT2A receptor occupancy, and neuroplastic effects in mice. J Psychopharmacol. 40, 81\u201394 (2026).","DOI":"10.1177\/02698811251395386"},{"key":"75890_CR58","doi-asserted-by":"crossref","unstructured":"Larsen, K. et al. Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans. J. Cereb. Blood Flow Metab. 45, 1385\u20131401 (2025).","DOI":"10.1177\/0271678X251323364"},{"key":"75890_CR59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1471-4159.1986.tb12933.x","volume":"46","author":"JJ Grome","year":"1986","unstructured":"Grome, J. J. & Harper, A. M. Local cerebral glucose utilisation following indoleamine- and piperazine-containing 5-hydroxytryptamine agonists. J. Neurochem 46, 117\u2013124 (1986).","journal-title":"J. Neurochem"},{"key":"75890_CR60","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41386-021-01207-y","volume":"47","author":"A Casado-Sainz","year":"2022","unstructured":"Casado-Sainz, A. et al. Dorsal striatal dopamine induces fronto-cortical hypoactivity and attenuates anxiety and compulsive behaviors in rats. Neuropsychopharmacology 47, 454\u2013464 (2022).","journal-title":"Neuropsychopharmacology"},{"key":"75890_CR61","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","volume":"16","author":"FX Vollenweider","year":"1997","unstructured":"Vollenweider, F. X. et al. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacol 16, 357\u2013372 (1997).","journal-title":"Neuropsychopharmacol"},{"key":"75890_CR62","doi-asserted-by":"crossref","unstructured":"Liu, J. et al. Acute psilocin increased cortical activity in rat. Front. Neurosci. 20, 1593703 (2026).","DOI":"10.3389\/fnins.2026.1593703"},{"key":"75890_CR63","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","volume":"28","author":"RE Daws","year":"2022","unstructured":"Daws, R. E. et al. Increased global integration in the brain after psilocybin therapy for depression. Nat. Med. 28, 844\u2013851 (2022).","journal-title":"Nat. Med"},{"key":"75890_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07527-8","volume":"7","author":"A R\u0103dulescu","year":"2017","unstructured":"R\u0103dulescu, A., Herron, J., Kennedy, C. & Scimemi, A. Global and local excitation and inhibition shape the dynamics of the cortico-striatal-thalamo-cortical pathway. Sci. Rep. 7, 7608 (2017).","journal-title":"Sci. Rep."},{"key":"75890_CR65","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.neuron.2015.12.032","volume":"89","author":"JK O\u2019Hare","year":"2016","unstructured":"O\u2019Hare, J. K. et al. Pathway-specific striatal substrates for habitual behavior. Neuron 89, 472\u2013479 (2016).","journal-title":"Neuron"},{"key":"75890_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02817-1","volume":"9","author":"JH Shin","year":"2018","unstructured":"Shin, J. H., Kim, D. & Jung, M. W. Differential coding of reward and movement information in the dorsomedial striatal direct and indirect pathways. Nat. Commun. 9, 404 (2018).","journal-title":"Nat. Commun."},{"key":"75890_CR67","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","volume":"20","author":"FX Vollenweider","year":"1999","unstructured":"Vollenweider, F. X., Vontobel, P., Hell, D. & Leenders, K. L. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man\u2014A PET study with [11C]raclopride. Neuropsychopharmacol 20, 424\u2013433 (1999).","journal-title":"Neuropsychopharmacol"},{"key":"75890_CR68","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1248\/bpb.b14-00315","volume":"38","author":"Y Sakashita","year":"2015","unstructured":"Sakashita, Y. et al. Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats. Biol. Pharm. Bull. 38, 134\u2013138 (2015).","journal-title":"Biol. Pharm. Bull."},{"key":"75890_CR69","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris, R. L. et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc. Natl. Acad. Sci. USA. 109, 2138\u20132143 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75890_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117456","volume":"225","author":"J Grandjean","year":"2021","unstructured":"Grandjean, J. et al. Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. NeuroImage 225, 117456 (2021).","journal-title":"NeuroImage"},{"key":"75890_CR71","doi-asserted-by":"crossref","unstructured":"Fuini, E. et al. Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats. Front. Neurosci. 19, 1554049 (2025).","DOI":"10.3389\/fnins.2025.1554049"},{"key":"75890_CR72","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/npp.2011.7","volume":"36","author":"DJ Lodge","year":"2011","unstructured":"Lodge, D. J. The medial prefrontal and orbitofrontal cortices differentially regulate dopamine system function. Neuropsychopharmacol 36, 1227\u20131236 (2011).","journal-title":"Neuropsychopharmacol"},{"key":"75890_CR73","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/nn.2957","volume":"14","author":"YK Takahashi","year":"2011","unstructured":"Takahashi, Y. K. et al. Expectancy-related changes in firing of dopamine neurons depend on orbitofrontal cortex. Nat. Neurosci. 14, 1590\u20131597 (2011).","journal-title":"Nat. Neurosci."},{"key":"75890_CR74","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41386-023-01744-8","volume":"49","author":"TJ Kelly","year":"2024","unstructured":"Kelly, T. J. et al. Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala. Neuropsychopharmacol 49, 854\u2013863 (2024).","journal-title":"Neuropsychopharmacol"},{"key":"75890_CR75","doi-asserted-by":"crossref","unstructured":"Ibrahim, C. et al. The Insula: a brain stimulation target for the treatment of addiction. Front. Pharmacol. 10, 720 (2019).","DOI":"10.3389\/fphar.2019.00720"},{"key":"75890_CR76","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1006\/nimg.2002.1087","volume":"16","author":"KL Phan","year":"2002","unstructured":"Phan, K. L., Wager, T., Taylor, S. F. & Liberzon, I. Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI. NeuroImage 16, 331\u2013348 (2002).","journal-title":"NeuroImage"},{"key":"75890_CR77","doi-asserted-by":"crossref","unstructured":"Barrett, F. S., Krimmel, S. R., Griffiths, R. R., Seminowicz, D. A. & Mathur, B. N. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage 218, 116890 (2020).","DOI":"10.1016\/j.neuroimage.2020.116980"},{"key":"75890_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56850-6","volume":"16","author":"F Aboharb","year":"2025","unstructured":"Aboharb, F. et al. Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression. Nat. Commun. 16, 1590 (2025).","journal-title":"Nat. Commun."},{"key":"75890_CR79","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/s41386-023-01613-4","volume":"48","author":"DR Rijsketic","year":"2023","unstructured":"Rijsketic, D. R. et al. UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice. Neuropsychopharmacol 48, 1798\u20131807 (2023).","journal-title":"Neuropsychopharmacol"},{"key":"75890_CR80","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1021\/acschemneuro.2c00637","volume":"14","author":"PA Davoudian","year":"2023","unstructured":"Davoudian, P. A., Shao, L.-X. & Kwan, A. C. Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin. ACS Chem. Neurosci. 14, 468\u2013480 (2023).","journal-title":"ACS Chem. Neurosci."},{"key":"75890_CR81","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuroimage.2017.07.020","volume":"159","author":"CR Lewis","year":"2017","unstructured":"Lewis, C. R. et al. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage 159, 70\u201378 (2017).","journal-title":"Neuroimage"},{"key":"75890_CR82","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1177\/0271678X15625349","volume":"36","author":"F Hyder","year":"2016","unstructured":"Hyder, F. et al. Uniform distributions of glucose oxidation and oxygen extraction in gray matter of normal human brain: No evidence of regional differences of aerobic glycolysis. J. Cereb. Blood Flow. Metab. 36, 903\u2013916 (2016).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"75890_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44153-z","volume":"13","author":"NM Rieser","year":"2023","unstructured":"Rieser, N. M. et al. Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences. Sci. Rep. 13, 17475 (2023).","journal-title":"Sci. Rep."},{"key":"75890_CR84","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/brain\/awab406","volume":"145","author":"MK Doss","year":"2021","unstructured":"Doss, M. K. et al. Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain 145, 441\u2013456 (2021).","journal-title":"Brain"},{"key":"75890_CR85","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider, F. X. & Preller, K. H. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat. Rev. Neurosci. 21, 611\u2013624 (2020).","journal-title":"Nat. Rev. Neurosci."},{"key":"75890_CR86","doi-asserted-by":"crossref","unstructured":"Huerga-G\u00f3mez, I., Martini, F. J. & L\u00f3pez-Bendito, G. Building thalamic neuronal networks during mouse development. Front. Neural Circuits 17, 1098913 (2023).","DOI":"10.3389\/fncir.2023.1098913"},{"key":"75890_CR87","doi-asserted-by":"publisher","unstructured":"Westlund, K. N. & Salt, T. E. Thalamic neurotransmitters and neuromodulators. in Encyclopedia of Pain (eds Gebhart, G. F. & Schmidt, R. F.) 3872\u20133882 (Springer, 2013); https:\/\/doi.org\/10.1007\/978-3-642-28753-4_4421.","DOI":"10.1007\/978-3-642-28753-4_4421"},{"key":"75890_CR88","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nn.4269","volume":"19","author":"SM Sherman","year":"2016","unstructured":"Sherman, S. M. Thalamus plays a central role in ongoing cortical functioning. Nat. Neurosci. 19, 533\u2013541 (2016).","journal-title":"Nat. Neurosci."},{"key":"75890_CR89","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 30, 1165\u20131180 (2016).","journal-title":"J. Psychopharmacol."},{"key":"75890_CR90","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.5114\/aoms.2019.85202","volume":"17","author":"X Zhuang","year":"2021","unstructured":"Zhuang, X. et al. The anterior cingulate cortex projection to the dorsomedial striatum modulates hyperalgesia in a chronic constriction injury mouse model. Arch. Med. Sci. 17, 1388\u20131399 (2021).","journal-title":"Arch. Med. Sci."},{"key":"75890_CR91","doi-asserted-by":"crossref","unstructured":"Minuzzi, L. Interaction between LSD and dopamine D2\/3 binding sites in pig brain. Synapse 56, 198\u2013204.","DOI":"10.1002\/syn.20141"},{"key":"75890_CR92","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","volume":"25","author":"AC Kwan","year":"2022","unstructured":"Kwan, A. C., Olson, D. E., Preller, K. H. & Roth, B. L. The neural basis of psychedelic action. Nat. Neurosci. 25, 1407\u20131419 (2022).","journal-title":"Nat. Neurosci."},{"key":"75890_CR93","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris, R. L. & Friston, K. J. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharm. Rev. 71, 316\u2013344 (2019).","journal-title":"Pharm. Rev."},{"key":"75890_CR94","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1016\/j.bmc.2009.03.021","volume":"17","author":"MM Herth","year":"2009","unstructured":"Herth, M. M. et al. Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg. Med. Chem. 17, 2989\u20133002 (2009).","journal-title":"Bioorg. Med. Chem."},{"key":"75890_CR95","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00259-019-04527-w","volume":"47","author":"V Kramer","year":"2020","unstructured":"Kramer, V. et al. Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain. Eur. J. Nucl. Med. Mol. Imaging 47, 355\u2013365 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"75890_CR96","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jneumeth.2006.01.027","volume":"155","author":"WK Schiffer","year":"2006","unstructured":"Schiffer, W. K. et al. Serial microPET measures of the metabolic reaction to a microdialysis probe implant. J. Neurosci. Methods 155, 272\u2013284 (2006).","journal-title":"J. Neurosci. Methods"},{"key":"75890_CR97","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.nucmedbio.2009.06.007","volume":"36","author":"MN Tantawy","year":"2009","unstructured":"Tantawy, M. N. et al. [18F]fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot. Nucl. Med Biol. 36, 931\u2013940 (2009).","journal-title":"Nucl. Med Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75890-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75890-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75890-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:03:07Z","timestamp":1788220987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75890-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75890"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75890-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P. owns shares in Compass Pathways Ltd and ATAI, is a scientific consultant for BrandarisTx, and has an ongoing research collaboration with Vibraint. He has previously carried out industry collaborations with Arla ApS, Cymab ApS, Tetrakit ApS, Compass Pathways Ltd and A7imuth. D.R.R. is an employee of TensorAnalytics, LLC. B.D.H. is a co-founder of Ocellaris Inc, is on the scientific advisory boards of Journey Clinical and Osmind, and is a paid consultant to Arcadia Medicine, Inc., Tactogen, LLC, and Vida Ventures, LLC. All other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9340"}}